Psychedelics
San Francisco to Decriminalize Psychedelics
The San Francisco Board of Supervisors has unanimously voted to decriminalize psychedelics like psilocybin and ayahuasca.
Psilocybin and Ketamine Are Safer Than Xanax, Say US Psychiatrists
Most American psychiatrists view psilocybin and ketamine as safer drugs than alprazolam (Xanax), methamphetamine, or alcohol, according to a new survey.
Psychedelic Drugs Lessen Fear of Dying, Study Suggests
A psychedelic drug experience may alter people’s perspectives on death and dying in a similar way to those who have survived a near-death experience, a new study has found.
Psilocybin-Assisted Therapy Can Treat Alcohol Use Disorder, Trial Finds
The first controlled trial of psilocybin for alcohol use disorder (AUD) reports that psilocybin-assisted psychotherapy significantly reduces the occurrence of heavy drinking days in people with AUD.
Research Suggests LSD May Enhance Learning and Memory
By studying human brain organoids — tissue cultures grown from stem cells that can mimic the developing brain — researchers have found that LSD regulates numerous processes related to neuroplasticity in the human brain.
Dual Action of Ketamine May Help Limit Addiction Risk
By demonstrating that ketamine induces only a brief increase in dopamine and does not alter neuronal communication, a team from the University of Geneva suggests that its therapeutic use may be safe.
Two Novel Chemical Entitities Show Early Potential for Significant Treatment Improvement in Depression
PSIL-001 and PSIL-002 show promising antidepressant effects without hallucinations while having improved learning and memory tendencies over a psilocybin mimic in a mouse model.
Basic Research and the Mechanism of Action of Ketamine
Dr Stephen Wright, a consultant in medicines development from Limber Strategic, explores the research behind ketamine.
One Month of Psilocybin Microdosing Improves Mood and Mental Health, Study Suggests
The microdosers in the study generally reported less depression, stress, and anxiety after one month of use, compared to their non-microdosing peers.
